Efficacy and safety of budesonide/formoterol Turbuhaler (160/4.5 mcg b.i.d. delivered dose) compared to budesonide Turbuhaler (200 mcg b.i.d. metered dose) in steroid-using asthmatic adolescent patients. A double-blind, double-dummy, randomised, parallel group, phase III, multicentre study

Study identifier:SD-039-0714

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Efficacy and safety of budesonide/formoterol Turbuhaler (160/4.5 mcg b.i.d. delivered dose) compared to budesonide Turbuhaler (200 mcg b.i.d. metered dose) in steroid-using asthmatic adolescent patients. A double-blind, double-dummy, randomised, parallel group, phase III, multicentre study

Medical condition

asthma

Phase

Phase 3

Healthy volunteers

-

Study drug

-

Sex

-

Actual Enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 Jul 2001
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria